ArticleInternal and emergency medicine2022
Changes in biomarkers of exposure and biomarkers of potential harm after 360 days in smokers who either continue to smoke, switch to a tobacco heating product or quit smoking.
Article in Internal and emergency medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Impact of heated tobacco products on biomarkers of potential harm and adverse events: a systematic review and meta-analysis.Tobacco control · 2026Pooled it
- The potential of new nicotine and tobacco products as tools for people who smoke to quit combustible cigarettes - a systematic review of common practices and guidance towards a robust study protocol to measure cessation efficacy.Harm reduction journal · 2024Pooled it
- Assessment of Abuse Liability and Nicotine Pharmacokinetics of glo Heated Tobacco Products in a Randomized, Crossover Study.European journal of drug metabolism and pharmacokinetics · 2024Trial
- An assessment of nicotine pharmacokinetics and subjective effects of the pulze heated tobacco system compared with cigarettes.Scientific reports · 2023Trial
- Relative affordability of heated tobacco products and cigarettes: a cross-country comparative analysis of 55 countries.Harm reduction journal · 2026Article
- A Narrative Review of the Potential Impact of Next-Generation Tobacco and Nicotine Products on Cardiovascular Health.Cureus · 2026Review
- Review
- Heated tobacco products vs conventional cigarettes: a scoping review of cardiovascular and respiratory clinical outcomes.Internal and emergency medicine · 2026Article
- Comparison of profiles of biomarkers of potential harm among healthy adults who used heated tobacco products, smoked combustible cigarettes, or who had never smoked: a cross-sectional, observational study.Internal and emergency medicine · 2026Observational
- Assessing the comparability of toxic emissions reduction from heated tobacco aerosols relative to cigarette smoke: a scientific approach to bridging datasets.Internal and emergency medicine · 2026Article
- Heated Tobacco Products: Emerging Health Outcomes and Insights into Oxidative Stress and Pro-Inflammatory-Driving Mechanisms.Antioxidants (Basel, Switzerland) · 2025Review
- Review
- The Health Effects of Heated Tobacco Product Use-A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Assessing biomarkers of exposure to carcinogens associated with combustible cigarettes, electronic cigarettes, and heated tobacco products: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Review
- Assessment of heated herbal products' tobacco harm reduction potential: pre-clinical and clinical studies.Frontiers in toxicology · 2025Article
- Cigarette smoking and alcohol-related liver disease.Liver research (Beijing, China) · 2024Review
- Article
- Article
- Review
- Protocol for the "magnitude of cigarette substitution after initiation of e-cigarettes and its impact on biomarkers of exposure and potential harm in dual users" (MAGNIFICAT) study.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate whether biomarkers of exposure (BoE) and potential harm (BoPH) are modified when smokers either continue to smoke or switch from smoking cigarettes to exclusive use of a tobacco heating product (THP) in an ambulatory setting over the period of a year, and to compare any changes with smokers who quit tobacco use completely and with never smokers' biomarker levels. Participants in this year-long ambulatory study were healthy smokers with a self-reported low intent to quit assigned either to continue smoking or switch to a THP; a group of smokers with a self-reported high intent to quit who abstained from tobacco use; and a group of never smokers. Various BoE and BoPH related to oxidative stress, cardiovascular and respiratory diseases and cancer were assessed at baseline and up to 360 days. Substantial and sustained reductions in BoE levels were found at 360 days for both participants who switched from smoking to THP use and participants who quit smoking, in many cases the reductions being of a similar order for both groups. The never smoker group typically had lower levels of the measured BoEs than either of these groups, and much lower levels than participants who continued to smoke. Several BoPHs were found to change in a favourable direction (towards never smoker levels) over the year study for participants who completely switched to THP or quit, while BoPHs such as soluble intercellular adhesion molecule-1 were found to change in an unfavourable direction (away from never smoker levels) in participants who continued to smoke. Our findings, alongside chemical and toxicological studies undertaken on the THP used in this study, lead to the conclusion that smokers who would have otherwise continued to smoke and instead switch entirely to the use of this THP, will reduce their exposure to tobacco smoke toxicants and as a consequence are reasonably likely to reduce disease risks compared to those continuing to smoke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.